{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T22:01:18Z","timestamp":1767045678347,"version":"3.40.5"},"reference-count":15,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Pegylated asparaginase may induce prolonged hypertriglyceridemia. To date, there is no standard management of this complication. Here, we present a case report of pegylated asparaginase-induced hypertriglyceridemia and hepatotoxicity successfully treated with continuous intravenous infusion of insulin and heparin. &lt;b&gt;&lt;i&gt;Case Presentation:&lt;\/i&gt;&lt;\/b&gt; A 51-year-old male patient with lymphoid blast crisis of chronic myelogenous leukemia was treated with pegylated asparaginase. The patient developed severe hypertriglyceridemia. Supportive therapy with low-fat diet, fibric acids, and omega-3 fatty acids was not successful, and later, the patient developed high-grade hepatotoxicity. Like hypertriglyceridemia-induced pancreatitis, continuous intravenous infusion of insulin and heparin was initiated. The level of triglyceride and cholesterol decreased rapidly within 4 days. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; In case of severe pegylated asparaginase-induced hypertriglyceridemia, continuous intravenous infusion of insulin and heparin can reduce rapidly and safely the triglyceride level. Controlled trials are needed to address this important issue.<\/jats:p>","DOI":"10.1159\/000505773","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T22:00:41Z","timestamp":1581458441000},"page":"210-214","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of Pegylated Asparaginase-Induced Hypertriglyceridemia with Continuous Intravenous Infusion of Insulin and Heparin: A Case Report"],"prefix":"10.1159","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-5564","authenticated-orcid":false,"given":"Nael","family":"Alakel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Heuschkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Balaian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1709"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/2359-3997000000068"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050497"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000297"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21571"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2010.898"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1067\/mlc.2001.117666"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-005-9006-z"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annfar.2004.06.006"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1590\/2359-3997000000244"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12659"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181f46c22"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711948"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2198-6"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-017-1478-0"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/505773","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/505773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:43:14Z","timestamp":1745422994000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000505773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,3,10]]},"published-print":{"date-parts":[[2020,3,17]]}},"URL":"https:\/\/doi.org\/10.1159\/000505773","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2019]]}}}